PubRank

Prospective Analysis of the Th17 Cellular Response in Pemphigus Vulgaris Patients

Clinical Trial ID NCT04096222

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04096222

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986 22.65
2 ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992 19.49
3 Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008 12.08
4 Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993 10.95
5 Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006 10.24
6 A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007 8.97
7 Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987 5.65
8 Mammalian ABC transporters in health and disease. Annu Rev Biochem 2001 4.90
9 Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989 4.66
10 Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014 2.98
11 Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007 2.90
12 Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990 2.86
13 ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A 1988 2.44
14 Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011 2.11
15 The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996 2.11
16 Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008 1.81
17 Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2006 1.76
18 The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986 1.71
19 A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci U S A 1998 1.62
20 Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000 1.58
21 P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994 1.55
22 Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 2005 1.54
23 High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000 1.47
24 Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011 1.13
25 Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996 1.11
26 ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 2009 1.05
27 Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2007 1.04
28 Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000 1.04
29 Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001 1.04
30 Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 1974 1.02
31 Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000 1.02
32 Adjuvant therapy of pemphigus. Arch Dermatol 1984 0.99
33 A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol 2012 0.93
34 Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 1992 0.93
35 Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2005 0.91
36 Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci 2008 0.90
37 Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996 0.88
38 Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 2000 0.88
39 Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J Immunol 2008 0.86
40 Cytokine networks in Pemphigus vulgaris: An integrated viewpoint. Autoimmunity 2012 0.85
41 Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clin Pharmacokinet 2015 0.85
42 Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol 2013 0.84
43 Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Clin Rheumatol 2009 0.84
44 Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995 0.82
45 Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol 2011 0.82
46 P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin. J Control Release 2008 0.81
47 Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res Ther 2015 0.81
48 CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology 2007 0.81
49 Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study. Mediators Inflamm 2014 0.80
50 The imbalance of Th17 and regulatory T cells in pemphigus patients. Eur J Dermatol 2014 0.80
51 Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur J Cancer 1993 0.79
52 "Pros and cons" on how to measure multidrug resistance in leukemias. Leuk Lymphoma 2002 0.79
53 The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. Iran J Allergy Asthma Immunol 2014 0.78
54 Constructing immunoprofiles to deconstruct disease complexity in pemphigus. Autoimmunity 2011 0.77
55 S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015 0.77
56 Lack of involvement of P-glycoprotein (P-gp) in pemphigus patients with poor response to steroid therapy. J Dermatol Sci 2002 0.77
57 Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed Pharmacother 2004 0.76
58 Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17/Treg cell in the immunopathogenesis of Pemphigus Vulgaris. Immunobiology 2015 0.76
59 P-glycoprotein in autoimmune rheumatic diseases. Autoimmun Rev 2015 0.76
60 Management of Pemphigus Vulgaris. Adv Ther 2016 0.75
61 Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp Hematol 2003 0.75
62 [Epidemiology of bullous pemphigoid in 32 years]. Gac Med Mex 2013 0.75
63 Aberrant epigenetic modifications in peripheral blood mononuclear cells from patients with pemphigus vulgaris. Br J Dermatol 2012 0.75
64 Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris. Mediators Inflamm 2017 0.75
65 Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunpathogenesis and Hopes for Non-Steroidal Treatment. Iran J Pharm Res 2017 0.75
66 Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia. Autoimmunity 2016 0.75
67 P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids. Int J Pharm 2017 0.75
68 Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. Nature 2017 0.75
69 Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. J Invest Dermatol 2017 0.75
70 Characterization of ABC transporters in human skin. Drug Metabol Drug Interact 2014 0.75
Next 100